Skip to content
DraconiticResearch
Search Sources API
197,761 studies31 sourcesUpdated 59 min ago
Peer-reviewedPublisher termsNature Cardiovascular Research

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy

25 more authors

Related

  1. Clinical effectiveness of mavacamten on cardiac function and disease-related indicators in patients with obstructive hypertrophic cardiomyopathy
    Ya-Nan Shi, Jia-Jia Huang, Hong-Zhi Liu +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossref
  2. Managing a mavacamten non-responder in obstructive hypertrophic cardiomyopathy: A case report
    Smita Scholtz, Felix Langkamp, Volker Rudolph +2
    Journal of cardiology casesPeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  3. Long-term mavacamten exposure reduces force and sarcomere density in a human induced pluripotent stem cell–derived model of hypertrophic cardiomyopathy
    Marianna Langione, Lucrezia Giammarino, Roberto Semeraro +16
    Cardiovascular ResearchPeer-reviewedLicence not statedFull textCardiovascular medicineHAL
  4. Therapeutic targeting of MYBPC3 mutation-specific hypertrophic cardiomyopathy guided by network modeling
    P. Luanpaisanon, C. M. Pavelec, L. A. Bradley +2
    bioRxivPreprintCC BYFull textPhysiologybioRxiv
  5. Mavacamten improves energy balance in a pre-clinical model of RASopathy-associated hypertrophic cardiomyopathy
    Andrea Ruiz-Velasco, Charlène Jouve, Lucille Deshayes +3
    Pediatric ResearchPeer-reviewedCC BY-NC-SA 4.0Full text1 citedGeneral biologyCardiovascular medicineHAL
BibTeX
@article{senmartin2026mavacamten,
  title = {{Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy}},
  author = {Laura Sen-Martín and Ángel Fernández-Trasancos and Miguel Á. López-Unzu and Agata Bak and Magdalena Zafra-Castellano and Rajiven Srikantharajah and Divya Pathak and Annika Klotz and Michel Kuehn and Alessia Ferrarini and Verónica Labrador-Cantarero and David Sánchez-Ortiz and María Rosaria Pricolo and Natalia Vicente and Diana Velázquez-Carreras and Lucía Sánchez-García and Jon Sicilia and José Ángel Nicolás-Ávila and María Sánchez-Díaz and Saskia Schlossarek and Lorena Cussó and Manuel Desco and María Villalba-Orero and Gabriela Guzmán-Martínez and Enrique Calvo and Roberto Barriales-Villa and Jesús Vázquez and Fátima Sánchez-Cabo and Andrés Hidalgo and Pieter de Tombe and Lucie Carrier and James Spudich and Kathleen Ruppel and Florian Weinberger and Olivier Cazorla and Anthony Hessel and Jorge Alegre-Cebollada},
  journal = {Nature Cardiovascular Research},
  year = {2026},
  month = jul,
  doi = {10.1038/s44161-026-00833-3},
  url = {https://hal.science/hal-05684926v1},
}
RIS
TY  - JOUR
TI  - Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy
AU  - Laura Sen-Martín
AU  - Ángel Fernández-Trasancos
AU  - Miguel Á. López-Unzu
AU  - Agata Bak
AU  - Magdalena Zafra-Castellano
AU  - Rajiven Srikantharajah
AU  - Divya Pathak
AU  - Annika Klotz
AU  - Michel Kuehn
AU  - Alessia Ferrarini
AU  - Verónica Labrador-Cantarero
AU  - David Sánchez-Ortiz
AU  - María Rosaria Pricolo
AU  - Natalia Vicente
AU  - Diana Velázquez-Carreras
AU  - Lucía Sánchez-García
AU  - Jon Sicilia
AU  - José Ángel Nicolás-Ávila
AU  - María Sánchez-Díaz
AU  - Saskia Schlossarek
AU  - Lorena Cussó
AU  - Manuel Desco
AU  - María Villalba-Orero
AU  - Gabriela Guzmán-Martínez
AU  - Enrique Calvo
AU  - Roberto Barriales-Villa
AU  - Jesús Vázquez
AU  - Fátima Sánchez-Cabo
AU  - Andrés Hidalgo
AU  - Pieter de Tombe
AU  - Lucie Carrier
AU  - James Spudich
AU  - Kathleen Ruppel
AU  - Florian Weinberger
AU  - Olivier Cazorla
AU  - Anthony Hessel
AU  - Jorge Alegre-Cebollada
PY  - 2026
DA  - 2026/07/07
JO  - Nature Cardiovascular Research
DO  - 10.1038/s44161-026-00833-3
UR  - https://hal.science/hal-05684926v1
SN  - 2731-0590
ER  -